Please use this identifier to cite or link to this item:
Title: A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
Authors: García-Gutiérrez, Valentín
Gómez-Casares, María T
Puerta, José M
Alonso-Domínguez, Juan M
Osorio, Santiago
Hernández-Boluda, Juan C
Collado, Rosa
Ramírez, María J
Ibáñez, Fátima
Martín, María L
Rodríguez-Gambarte, Juan D
Martínez-Laperche, Carolina
Gómez, Montse
Fiallo, Dolly V
Redondo, Sara
Rodríguez, Alicia
Ruiz-Nuño, Concepción
Steegmann, Juan L
Jiménez-Velasco, Antonio
Spanish Group of Chronic Myeloid Leukemia (GELMC)
metadata.dc.subject.mesh: Adult
Biomarkers, Tumor
Cohort Studies
Follow-Up Studies
Fusion Proteins, bcr-abl
Gene Rearrangement
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Neoplasm Staging
Polymerase Chain Reaction
Protein Kinase Inhibitors
Issue Date: 9-Mar-2017
Abstract: In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with standardized RQ-PCR (IS) when measuring BCR-ABL1 levels lower than 10%, as it is not accurate for values over 10%. The aim of the present study was to determine the predictive molecular value at three months on different outcome variables using the Xpert BCR-ABL1 MonitorTM assay (Xpert BCR-ABL1). We monitored 125 newly diagnosed consecutive CML patients in the chronic phase (CML-CP) using an automated method: Xpert BCR-ABL1. Only 5% of patients did not achieve an optimal response at 3 months, and the 10% BCR-ABL1 cutoff defined by RQ-PCR (IS) methods was unable to identify significant differences in the probabilities of achieving a complete cytogenetic response (CCyR) (50% vs. 87%, p = 0.1) or a major molecular response (MMR) (60% vs. 80%, p = 0.29) by 12 months. In contrast, a cutoff of 1.5% more accurately identified differences in the probabilities of achieving CCyR (98% vs. 54%, p
metadata.dc.identifier.doi: 10.1371/journal.pone.0173532
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5344481.pdf767,75 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons